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Abstract
Background: Previous gene-environment interaction studies of breast cancer risk have
provided sparse evidence of interactions. Using the largest available dataset to date,
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we performed a comprehensive assessment of potential effect modification of 205 com-
mon susceptibility variants by 13 established breast cancer risk factors, including repli-
cation of previously reported interactions.
Methods: Analyses were performed using 28 176 cases and 32 209 controls genotyped
with iCOGS array and 44 109 cases and 48 145 controls genotyped using OncoArray
from the Breast Cancer Association Consortium (BCAC). Gene-environment interactions
were assessed using unconditional logistic regression and likelihood ratio tests for
breast cancer risk overall and by estrogen-receptor (ER) status. Bayesian false discovery
probability was used to assess the noteworthiness of the meta-analysed array-specific
interactions.
Results: Noteworthy evidence of interaction at 1% prior probability was observed
for three single nucleotide polymorphism (SNP)-risk factor pairs. SNP rs4442975
was associated with a greater reduction of risk of ER-positive breast cancer [odds ratio
(OR)int ¼ 0.85 (0.78-0.93), Pint ¼ 2.8 x 10
–4] and overall breast cancer [ORint ¼ 0.85
(0.78-0.92), Pint ¼ 7.4 x 10
–5) in current users of estrogen-progesterone therapy
compared with non-users. This finding was supported by replication using OncoArray
data of the previously reported interaction between rs13387042 (r2 ¼ 0.93 with
rs4442975) and current estrogen-progesterone therapy for overall disease (Pint ¼
0.004). The two other interactions suggested stronger associations between SNP
rs6596100 and ER-negative breast cancer with increasing parity and younger age at
first birth.
Conclusions: Overall, our study does not suggest strong effect modification of common
breast cancer susceptibility variants by established risk factors.
Key words: Gene-environment interaction, breast cancer, single nucleotide polymorphism, epidemiology, risk
factors, Europeans
Introduction
Breast cancer is a complex disease with both environmen-
tal and genetic factors contributing to risk. Well-
established modifiable and non-modifiable environmental
factors include age at menarche, parity, age at first birth,
breastfeeding, body mass index (BMI), use of menopausal
hormonal therapy (MHT) and alcohol consumption.1–6
In addition, high/moderate-risk gene mutations such as
BRCA1, BRCA2, TP53, ATM and CHEK2 increase the
risk of breast cancer,7–14 as well as multiple common,
low-risk single nucleotide polymorphisms (SNPs) discov-
ered through genome-wide association studies (GWAS).
Approximately 170 genome-wide significant breast cancer
susceptibility loci have been identified, including the
recently published 65 novel loci associated with overall
breast cancer and 10 loci with estrogen receptor
Key Messages
• The association between common breast cancer susceptibility loci and breast cancer risk is not strongly modified by
established breast cancer risk factors.
• The combined effect of susceptibility loci and established risk factors is thus well described by a multiplicative
model.
• We found one noteworthy gene-environment (G x E) interaction with overall and with estrogen-receptor-positive
breast cancer risk, which was replicated, and two novel noteworthy G x E interactions with ER-negative breast cancer
risk.
• In an independent dataset, we replicated two previously reported G x E interactions.
2 International Journal of Epidemiology, 2019, Vol. 0, No. 0
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(ER)-negative breast cancer risk, identified through the
OncoArray project.15,16
Estimation of any combined effect of genetic and envi-
ronmental factors, including gene-environment (G x E)
interactions, is considered to possibly improve breast cancer
risk prediction, and hence identification of women at
high risk for targeted prevention. However, development
of these risk models depends on knowledge of the joint
effects of genetic and environmental risk factors, in
particular departures from a multiplicative model (that is,
G x E interaction on relative risk scale).17 More impor-
tantly, G x E studies of individual susceptibility loci may
also provide insight on potential underlying biological
mechanisms that could mediate causal effects of a factor
on risk of breast cancer.
Previous G x E interaction studies of breast cancer have
reported nearly 30 potential G x E interactions, with little
evidence of departures from the multiplicative model.18,19
Most reported G x E interactions for breast cancer have
not been replicated in independent datasets. Two G x E
interactions were replicated using data from the Breast
Cancer Association Consortium (BCAC),20 but were not
replicated in a smaller study by the Breast and Prostate
Cancer Cohort Consortium.21 In this study, we assess
interactions between 205 known common breast cancer
susceptibility loci and 13 established environmental risk
factors in relation to risk of overall and of ER-specific
breast cancer for women of European ancestry, using the
largest available dataset to date from the Breast Cancer
Association Consortium (BCAC). Additionally, we
attempted to replicate previously reported potential G x E
interactions.18
Materials and Methods
Study population
We analysed data from 46 studies (16 prospective cohorts,
14 population-based case-control studies and 16 non-
population based studies) participating in BCAC
(Supplementary Table 1, available as Supplementary data
at IJE online). Participants were excluded if they were
male, were of non-European descent, had breast tumours
of unknown invasiveness, or had in situ disease or preva-
lent disease at the time of assessment. Women with un-
known age at reference date (defined as date of diagnosis
for cases and of interview for controls) were also excluded.
For each risk factor, only studies with risk factor informa-
tion for at least 150 cases and 150 controls were included.
All participating studies were approved by the relevant
ethics committees and informed consent was obtained
from study participants.
Data harmonization and variable definition
Data for risk factors from different studies were harmo-
nized according to a common data dictionary and were
centrally quality controlled. For both case-control and co-
hort studies, epidemiological risk factor data were derived
with reference to reference date (described above). We
used reference age as surrogate to categorize women as
probably premenopausal (<54 years) or postmenopausal
(54 years) status. The environmental variables available
for analysis were: age at menarche (per 2 years); ever par-
ous (yes or no); for parous women, number of full-term
pregnancies (1, 2, 3 and 4), age at first full-term preg-
nancy (per 5 years), ever breastfed (yes or no), duration of
breastfeeding (per 12months); and for all women, ever use
of oral contraceptives (yes or no), adult body mass index
(BMI) separately for pre- and postmenopausal women (per
5 kg/m2), adult height (per 5 cm), lifetime alcohol con-
sumption (per 10 g/day), current smoking (yes or no) and
current use of combined estrogen-progesterone meno-
pausal hormonal therapy (MHT) (yes or no) as well as cur-
rent use of estrogen-only MHT (yes or no) for
postmenopausal women.
Genetic data
Samples were genotyped using one of the two SNP arrays:
iCOGS22 or OncoArray.15 Included in the analyses were
28 176 cases and 32 209 controls of European ancestry
genotyped by the custom iSelect genotyping array
(iCOGS), comprising 211 155 SNPs,22 and 44 109 cases
and 48 145 controls genotyped using the OncoArray
500K, comprising 533 000 SNPs, nearly 260 000 of which
were selected as a ‘GWAS backbone’ (Illumina
HumanCore).23 These data were used to impute genotypes
for 11.8M SNPs using the 1000 Genomes Project (phase
3 version 5) reference panel.15,16 Details of genotyping and
quality control procedures for the iCOGS and OncoArray
projects are described in more detail elsewhere.15,22,23
A total of 205 common breast cancer susceptibility var-
iants were selected for evaluation of G x E interactions
(Supplementary Table 2, available as Supplementary data
at IJE online). These variants have been associated with
breast cancer risk either through GWAS24–34 or by fine
mapping of associated regions.35–52 Of these, 72 were
identified through the OncoArray project and had not
been previously evaluated for G x E interactions.15,16
For replication of the previously reported interactions,
we analysed a subset of 30 544 cases and 37 616 controls
genotyped using the OncoArray array, which had not been
included in previous G x E studies. We evaluated 33 poten-
tial G x E interactions that had been previously reported
International Journal of Epidemiology, 2019, Vol. 0, No. 0 3
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(Supplementary Table 3, available as Supplementary data
at IJE online).18
Statistical analysis
Unconditional logistic regression analysis was employed to
assess associations of SNPs and risk factors with breast
cancer risk. For SNPs, the estimated number of minor
alleles based on imputation was included as a continuous
variable. SNP-risk factor interactions were assessed using
likelihood ratio tests, based on unconditional logistic re-
gression models with and without an interaction term
between the SNP and risk factor of interest. All analyses
were adjusted for study, reference age and 10 ancestry-
informative principal components. To account for
differential main effects of risk factors by study design, we
included an interaction term between the risk factor of
interest and an indicator variable for study design (popu-
lation-based and non-population-based), along with the
main effect for study design.
Analyses were conducted separately for overall breast
cancer risk and for ER subtype-specific breast cancer risk.
The analyses were performed separately for women geno-
typed by iCOGS or OncoArray, and the results were meta-
analysed using a fixed-effects inverse-variance weighted
model. Between-study heterogeneity in the G x E interac-
tion effect estimates was assessed by Cochrane’s Q test and
I2 index.
MHT was classified into estrogen-progesterone therapy
(EPT) and estrogen-only therapy (ET). Models assessing
the association with current MHT use by type were ad-
justed for former use of MHT and use of any MHT prepa-
ration other than the one of interest. All analyses of MHT
use were restricted to postmenopausal women. Models
evaluating the association with current smoking were ad-
justed for former smoking.
To assess the noteworthiness of the observed G x E
interactions, we calculated Bayesian false discovery proba-
bility (BFDP) at five different prior probabilities for a true
association (20%, 10%, 1%, 0.1% and 0.01%). G x E
interactions with BFDP <80% were considered as note-
worthy. This was based on the assumption of a 4-fold cost
of a false non-discovery compared with the cost of a false
discovery and that the probability of observing a true inter-
action odds ratio (OR) inside the range of 0.66-1.50 was
95%, as proposed by Wakefield et al.53 We also computed
a complementary measure to BFDP known as approximate
Bayes factor (ABF). This approximates the ratio of the
probability of the data given that the null hypothesis is true
to the probability of the data when the alternative hypothe-
sis is true, the null hypothesis being absence of any interac-
tion. Therefore, a lower ABF favours the alternative
hypothesis over the null hypothesis of absence of an inter-
action. For noteworthy G x E interactions, we performed
stratified analyses by categories of the environmental risk
factor using logistic regression. Analyses were carried out
using SAS 9.4 or R version 3.4.2. Meta-analyses and tests
of between-study heterogeneity were conducted using the
R package ‘meta’ (version 4.9–2).
Results
The studies included in this analysis are listed in
Supplementary Table 1, available as Supplementary data
at IJE online. The number of cases and controls with data
for each risk factor varied, ranging from 23 755 cases and
30 153 controls with data for parity to 5078 cases and
6867 controls with data for cumulative lifetime intake of
alcohol in the iCOGS dataset, and from 37 863 cases and
44 533 controls with data for parity to 12 213 cases and
13 232 controls with data for lifetime alcohol intake in the
OncoArray dataset (Supplementary Tables 4 and 5, avail-
able as Supplementary data at IJE online).
The SNP associations with risk of overall as well as ER
subtype breast cancer were consistent with those reported
in literature15,16 (Supplementary Tables 2 and 3, available
as Supplementary data at IJE online). The associations of
the environmental risk factors with breast cancer risk were
as expected in the population-based studies; in brief, age at
menarche, being parous, number of full-term pregnancies,
ever breastfeeding, cumulative duration of breastfeeding
and premenopausal BMI were negatively associated with
breast cancer risk, whereas age at first full-term pregnancy,
ever use of oral contraceptives, postmenopausal BMI, cur-
rent use of EPT, adult height, current smoking and cumula-
tive alcohol consumption were all positively associated
with breast cancer risk (Table 1; Supplementary Figures
1–3, available as Supplementary data at IJE online).
We identified three SNP-risk factor interactions as note-
worthy (BFDP <0.8) at 1% prior probability (Table 2).
The strongest G x E interaction was found for SNP
rs4442975 and current use of EPT [ORmeta-int ¼ 0.85,
95% confidence interval (CI) ¼ 0.78-0.92, Pmeta-int ¼ 7.4 x
10–5, BFDP ¼ 0.73] with overall breast cancer at 0.1%
prior probability. The minor allele of SNP rs4442975 was
associated with a stronger reduced risk of breast cancer for
current users of EPT (ORmeta ¼ 0.74, 95% CI ¼ 0.69-
0.80) than for never users of MHT (ORmeta ¼ 0.87, 95%
CI ¼ 0.84-0.90) (Figure 1A). This interaction was also
found to be noteworthy at 1% prior probability for risk of
ER-positive breast cancer (ORmeta-int ¼ 0.85, 95% CI ¼
0.78-0.93, Pmeta-int ¼ 2.8 x 10
–4, BFDP ¼ 0.46). The asso-
ciation of rs4442975 with reduced risk of ER-positive
breast cancer was stronger for current users of EPT
4 International Journal of Epidemiology, 2019, Vol. 0, No. 0
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(ORmeta ¼ 0.73, 95% CI ¼ 0.68-0.79) than for never
MHT users (ORmeta ¼ 0.86, 95% CI ¼ 0.83-0.89)
(Figure 1B).
The two other noteworthy SNP-risk factor interactions
were found for ER-negative breast cancer risk. The interac-
tion between rs6596100 and number of full-term pregnan-
cies was noteworthy at 1% prior probability (ORmeta-int ¼
0.91, 95% CI ¼ 0.85-0.96, Pmeta-int ¼ 8.2 x 10
–4, BFDP ¼
0.74). The minor allele of the rs6596100 variant was asso-
ciated with a reduced risk of overall breast cancer (ORmeta
¼ 0.96, 95% CI ¼ 0.94-0.98) and ER-positive breast
cancer (ORmeta ¼ 0.94, 95% CI ¼ 0.92-0.96), respectively,
but not ER-negative breast cancer (ORmeta ¼ 1.01, 95%
CI ¼ 0.97-1.05). The rs6596100 associated risk of
ER-negative breast cancer appears to decrease with num-
ber of full-term pregnancies for parous women, with the
estimated per-allele ORmeta being 1.06 (95% CI ¼ 0.95-
1.17) for women who had had one full-term pregnancy
and 0.92 (95% CI ¼ 0.82-1.04) for women who had had
four or more full-term pregnancies (Figure 1C).
For parous women, we observed noteworthy evidence
that the ER-negative breast cancer risk associated with
rs6596100 was also modified by age at first full-term preg-
nancy (ORmeta-int ¼ 1.12, 95% CI ¼ 1.05-1.19, Pmeta-int ¼
3.3 x 10–4, BFDP ¼ 0.56). The risk conferred by
rs6596100 on ER-negative breast cancer was decreased for
women with age at first full-term pregnancy below
20 years (ORmeta ¼ 0.90, 95% CI ¼ 0.79-1.03) but
increased for women with age at first full-term pregnancy
30 years (ORmeta ¼ 1.10, 95% CI ¼ 0.97-1.24)
(Figure 1D). However, we observed between-study hetero-
geneity for the interaction between rs6596100 and age at
first full-term pregnancy (Supplementary Figure 4, avail-
able as Supplementary data at IJE online). Several other
interactions were found to be noteworthy (BFDP <0.8) at
5% prior probability (Supplementary Table 6, available as
Supplementary data at IJE online). Meta-analysed results
of all the G x E interactions for overall and ER subtype
risk are shown in Supplementary Tables 7–9, available as
Supplementary data at IJE online.
Table 1.Main effects for the epidemiological variables included in the analyses, derived from population-based studies only
Environmental risk factor Overall breast cancer risk ER-positive breast cancer risk ER-negative breast cancer risk
Cases/controls OR (95% CI) Cases/controls OR (95% CI) Cases/controls OR (95% CI)
Age at menarche
(per 2 years)
36 893/46 854 0.91 (0.89-0.92) 26 630/46 854 0.91 (0.89-0.93) 4255/25 233 0.89 (0.85-0.93)
Ever parous (yes/no) 37 242/47 173 0.81 (0.77-0.84) 26 937/47 173 0.78 (0.74-0.81) 4309/25 585 0.94 (0.85-1.04)
Number of full-term
pregnancies (1, 2, 3, 4)
31 390/41 215 0.87 (0.85-0.88) 22 720/41 215 0.86 (0.84-0.87) 3273/18 267 0.90 (0.86-0.94)
Age at first full-term
pregnancy (per 5 years)a
30 168/39 850 1.14 (1.12-1.16) 21 869/39 850 1.17 (1.14-1.19) 3472/21 422 1.02 (0.97-1.06)
Ever breastfed (yes/no)a 27 786/30 582 0.91 (0.88-0.95) 19 691/30 582 0.92 (0.88-0.96) 3533/19 606 0.96 (0.88-1.03)
Duration of breastfeeding
(per 12 months)a
24 553/25 524 0.96 (0.93-0.98) 17 355/25 524 0.95 (0.93-0.98) 3315/18 012 0.98 (0.94-1.03)
Adult height (per 5 cm) 35 767/46 506 1.09 (1.08-1.10) 25 763/46 506 1.10 (1.09-1.12) 3954/24 342 1.03 (1.00-1.05)
Premenopausal BMI
(per 5 kg/m2)
7994/10 066 0.95 (0.92-0.98) 4835/9490 0.92 (0.89-0.95) 913/2030 1.07 (0.98-1.16)
Postmenopausal BMI
(per 5 kg/m2)
27 495/32 495 1.07 (1.05-1.09) 20 503/32 283 1.07 (1.05-1.09) 1758/11 859 1.05 (1.00-1.11)
Ever use of oral
contraceptives (yes/no)
35 126/44 608 1.22 (1.18-1.26) 25 271/44 608 1.24 (1.20-1.29) 3939/24 225 1.14 (1.05-1.23)
Current use of EPT (yes/no)b,c 16 637/17 946 1.75 (1.65-1.87) 12 566/17 946 1.93 (1.81-2.06) 1190/7353 1.11 (0.92-1.34)
Current use of ET (yes/no)b,c 16 444/17 920 1.10 (1.03-1.17) 11 829/16 844 1.11 (1.03-1.19) 936/6262 1.35 (1.11-1.64)
Lifetime intake of alcohol
(per 10 g/day)
15 827/18 723 1.07 (1.05-1.10) 11 302/18 723 1.09 (1.07-1.11) 1612/11 562 1.03 (0.98-1.08)
Current smoking (yes/no)d 33 737/43 222 1.18 (1.13-1.24) 24 123/43 222 1.18 (1.12-1.25) 3707/22 573 1.06 (0.96-1.18)
Pack years smoked
(per 10 pack-years)e
79 75/11 709 1.02 (1.00-1.04) 5944/11 709 1.02 (1.00-1.04) 896/6400 1.00 (0.95-1.04)
All models were adjusted for reference age and study.
aAmong parous women.
bAmong postmenopausal women.
cAdditionally, models were adjusted for former use of menopausal hormonal therapy and use of any other menopausal hormonal therapy preparations.
dAdditionally, model was adjusted for former smoking.
eAmong ever smokers.
International Journal of Epidemiology, 2019, Vol. 0, No. 0 5
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/ije
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/ije
/d
y
z
1
9
3
/5
5
8
6
5
5
6
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 1
6
 O
c
to
b
e
r 2
0
1
9
In replication analyses, we found evidence for two pre-
viously reported associations in the independent subset of
OncoArray data (Supplementary Table 10, available as
Supplementary data at IJE online). We estimated an inter-
action OR for overall breast cancer of 0.80 (95% CI ¼
0.69-0.93, Pint ¼ 0.004) for current EPT use and
rs13387042, a SNP for which we had previously reported
an interaction OR of 0.83 (95% CI ¼ 0.74-0.94, Pint ¼
2.43 x 10–3).20 SNP rs13387042 is in strong linkage dis-
equilibrium with rs4442975; hence this result is consistent
with the interaction observed for rs4442975 in the full
dataset. In addition, we also observed evidence for a G x E
interaction between rs941764 and cumulative lifetime in-
take of alcohol (<20 g/day vs 20 g/day) with ER-negative
breast cancer risk (ORint ¼ 0.64, 95% CI ¼ 0.45-0.92, Pint
¼ 0.01), compared with ORint of 0.53 (95% CI ¼ 0.36-
0.76, Pint ¼ 6.8 x 10
–4) in Rudolph et al.54 The corre-
sponding meta-analysed interaction OR (per 10 g/day cu-
mulative lifetime alcohol intake) based on OncoArray and
iCOGS datasets was 0.90 (95% CI ¼ 0.81-0.99, Pint ¼
0.03). For the G x E interaction between SNP rs3817198
and number of children for parous women, which had the
strongest evidence for overall risk of breast cancer in previ-
ous analyses (ORint ¼ 1.06, 95% CI ¼1.04-1.08, Pint ¼
2.4 x 10–06),20 there was weak evidence of interaction, but
in the opposite direction in the replication analyses (ORint
¼ 0.94, 95% CI ¼ 0.94-1.00, Pint ¼ 0.03).
Discussion
In this study, we evaluated all known common susceptibil-
ity loci for interactions with breast cancer risk factors, and
found little evidence for departures from a multiplicative
model. We refer to G x E interactions as effect modifica-
tion conferred by epidemiological risk factors on the asso-
ciation between SNPs and breast cancer risk, but it can
very well be SNPs modifying the association of risk factors
with breast cancer risk. We identified three noteworthy
(BFDP <0.8) G x E interactions related to breast cancer
risk based on prior probabilities 1%. The strongest evi-
dence was found for effect modification between
rs4442975 and current use of EPT with overall and ER-
positive breast cancer risk. Moreover, we found evidence
of interactions between the SNP rs6596100 and number of
full-term pregnancies and age at first full-term pregnancy,
respectively, for ER-negative breast cancer risk.
The SNP rs4442975 is located in an intergenic region
on the long arm of chromosome 2 (2q35). Another SNP
within the same genomic region, rs13387042, was previ-
ously reported to show an interaction also with current use
of EPT.20 We replicated this interaction between
rs13387042 and current use of EPT using the OncoArrayTa
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dataset. The two SNPs rs13387042 and rs4442975 are
highly correlated (r2 ¼ 0.93) and conditional analysis
yielded a significant association only for rs4442975, so
that these results reflect the same interaction. Fine-
mapping and functional analyses have identified
rs4442975 to be the most likely causal variant in this re-
gion.43 Thus despite the small difference in the risk esti-
mates between never and current EPT, replication of this
G x E interaction reinforced what we found previously,
implicating the role of the IGFBP5 gene and estrogen
pathway in breast cancer.
Functional analyses indicate that SNP rs4442975 lies
near a transcriptional enhancer which physically interacts
with the IGFBP5 promoter, suggesting that the T-allele of
rs4442975 decreases susceptibility to breast cancer via in-
creased expression of insulin-like growth factor binding
protein 5 (IGFBP5).43 IGFBP5 is a key member of the
insulin-like growth factor (IGF) axis which plays an
important role in cellular differentiation, proliferation and
apoptosis in breast cancer.55 Activation of the IGF
receptors by IGF causes phosphorylation of insulin recep-
tor substrates (IRS-1 and IRS-2). This phosphorylation
cascades multiple downstream signalling pathways such
as Ras/mitogen-activated protein kinase (MAPK) and
phosphoinositide (PI3K) serine-threonine kinase (AkT),
which play a role in breast carcinogenesis.56,57 Estrogen
can stimulate the IGF pathway via increased expression of
both insulin-like growth factor receptor-1 and IRS-1. Some
studies have also reported a positive correlation between
overexpression of IGFBP5 and the presence of ER in breast
cancer cell lines. Progesterone has been shown to act by in-
creasing levels of IRS-2 and sensitizing breast cancer cells
to downstream signalling pathways such as MAPK and
Akt.58–60 It is plausible that exogenous hormone exposure
due to estrogen and progesterone therapy may affect the
regulation of the IGF pathway and thereby modulate germ-
line IGFPB5 variant-related susceptibility to breast cancer.
Note however that two other independent breast cancer
Figure 1. Odds ratios and 95% confidence intervals for associations between SNP and overall breast cancer (A), ER-positive breast cancer (B) and ER-
negative breast cancer (C, D), stratified by categories of environmental risk factors.
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9
risk variants in this region (tagged by rs1685760913 and a
1.3 kb insertion/deletion49) are also believed to target
IGFBP5, but we did not find evidence for interactions
between these variants and current EPT use.
Women of young age at first pregnancy are known to
have increased circulating sex hormone-binding globulin
and prolactin but decreased total estrogen levels.61,62
Likewise, women who have had multiple full-term preg-
nancies have an overall decreased lifetime exposure to
estrogen.61,63,64 The association of rs6596100 with ER-
negative breast cancer risk was found to be modified by
number of full-term pregnancies and age at first full-term
pregnancy for parous women. Based on INQUISIT,15 the
target genes of rs6596100 and highly correlated SNPs are
predicted to be heat shock protein family A member 4
(HSPA4) and AF4/FMR2 family member 4 (AFF4).
INQUISIT predicts HSPA4 as the most likely target, due to
overlap of multiple correlated SNPs lying in HSPA4
promoter region, distal regulatory elements and coding
sequence. HSPA4 gene is responsible for production of
heat shock proteins (Hsps), particularly those belonging to
the family HSP70. The underlying mechanisms regarding
the relationship between rs6596100 and these pregnancy-
related risk factors are unknown at present. It is plausible
that a lower estrogenic milieu due to reproductive factors
may affect the formation of multicomplexes between ste-
roid receptors like ER and heat shock proteins (HSPs),
therefore affecting signalling pathways such as Wnt, ErbB,
serine/threonine and tyrosine protein kinase, which are
known to be involved in breast carcinogenesis. Whereas
there is some biological plausibility regarding the observed
interactions with rs6596100, the findings nevertheless
could be by chance, and thus require independent
replication.
The SNP rs941764 is located on chromosome 14 in in-
tron of CCDC88C gene.15,22 The effect modification of
rs941764-associated ER-negative breast cancer risk by
lifetime intake of alcohol was first reported by Rudolph
et al.54 We replicated this G x E interaction in an indepen-
dent dataset in our study. Mutations in this gene region
have been associated with dysregulation of Wnt signalling
in neural disorders such as congenital hydrocephalus.65
This gene codes a Hook-related protein (HkRP2) that
binds to an important scaffold protein, Dishevelled, in
the Wnt signalling pathway, affecting all downstream
activity.65
A role of alcohol has been well recognized in initiation
and progression of breast cancer, presumably via multiple
cellular and molecular mechanisms, including the EGFR/
ErbB2 pathways. Downstream to EGFR/ErbB2 pathways
lie multiple pathways such as the MAPK, Wnt/GSK3b/b-
catenin pathways.66 Therefore, alcohol consumption could
affect the risk of ER-negative breast cancer through
dysregulation of Wnt signalling.
Our study provides the most comprehensive evaluation
to date of potential effect modification of all known
common genetic susceptibility variants by environmental
risk factors for breast cancer. Our findings are based on
the largest available dataset on breast cancer. Despite its
large sample size, the study may remain statistically under-
powered, considering the rather modest effect sizes of most
of the common variants associated with breast cancer risk,
and particularly for risk factors for which we have fewer
data (Supplementary Table 11, available as Supplementary
data at IJE online).18 Statistical power was further dimin-
ished for subtype-specific analyses due to reduced sample
sizes, especially for ER-negative breast cancer (10 896 ER-
negative cases in the combined iCOGS and OncoArray
dataset).18 The lack of strong effect modifications for
breast cancer could also be explained by the overall weak
to moderate associations of environmental risk factors,
except for MHT use with breast cancer risk along with the
modest associations of common genetic variants. A further
limitation of our study is that the findings may not be gen-
eralizable to other racial/ethnic groups since the analyses
were restricted to women of European ancestry.
In conclusion, our analyses suggest that most of the as-
sociated effects of breast cancer susceptibility loci and envi-
ronmental risk factors are consistent with a multiplicative
model. The strongest evidence for an interaction was be-
tween the candidate causal variant rs4442975 at 2q35 and
current use of EPT. The associated effect is supported by a
plausible underlying biological mechanism, but further epi-
demiological and functional validation will be required to
determine whether the interaction is genuine. The newly
reported results for ER-negative breast cancer risk generate
plausible biological hypotheses and may inform future
functional studies. Overall, the results from our analyses
do not suggest strong effect modification of the association
between breast cancer susceptibility loci and risk of breast
cancer by established epidemiological risk factors.
Supplementary data
Supplementary data are available at IJE online.
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